Weight gain in the treatment of mood disorders - PubMed (original) (raw)

Affiliations

• PMID: 12892538

Review

Weight gain in the treatment of mood disorders

Louis J Aronne et al. J Clin Psychiatry. 2003.

Abstract

Overweight and obesity have become an urgent public health problem in the United States: approximately 61% of the adult population (97 million adults) are overweight or obese, where overweight is defined as a body mass index (BMI) >/= 25 and obesity is defined as a BMI >/= 30. Overweight and obesity increase the risk for developing many serious chronic diseases such as cardiovascular disease, type 2 diabetes, hypertension, dyslipidemia, and certain cancers. Increased morbidity due to obesity-related disorders begins within the normal weight range. Weight gain in adulthood per se, even in individuals who are normal weight, has deleterious health effects. Medications, particularly those commonly used in psychiatry and neurology, are a significant iatrogenic source of overweight and obesity. The weight gain potential of prescription medications should be considered in order to enhance patient compliance and reduce the risk of metabolic sequelae of weight gain. This article provides an overview of the weight-gain potential of several classes of drugs commonly used in psychiatric practice and considerations for clinicians in prescribing these medications.

PubMed Disclaimer

Similar articles

• Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
  Torrent C, Amann B, Sánchez-Moreno J, Colom F, Reinares M, Comes M, Rosa AR, Scott J, Vieta E. Torrent C, et al. Acta Psychiatr Scand. 2008 Jul;118(1):4-18. doi: 10.1111/j.1600-0447.2008.01204.x. Epub 2008 May 22. Acta Psychiatr Scand. 2008. PMID: 18498432 Review.
• Weight gain associated with use of psychotropic medications.
  Sachs GS, Guille C. Sachs GS, et al. J Clin Psychiatry. 1999;60 Suppl 21:16-9. J Clin Psychiatry. 1999. PMID: 10548137 Review.
• A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
  McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck PE Jr. McElroy SL, et al. Bipolar Disord. 2007 Jun;9(4):426-34. doi: 10.1111/j.1399-5618.2007.00488.x. Bipolar Disord. 2007. PMID: 17547588 Clinical Trial.
• Schizophrenia and obesity: impact of antipsychotic medications.
  Wirshing DA. Wirshing DA. J Clin Psychiatry. 2004;65 Suppl 18:13-26. J Clin Psychiatry. 2004. PMID: 15600381 Review.
• Metabolic risk during antipsychotic treatment.
  Newcomer JW. Newcomer JW. Clin Ther. 2004 Dec;26(12):1936-46. doi: 10.1016/j.clinthera.2004.12.003. Clin Ther. 2004. PMID: 15823759 Review.

Cited by

• Long-Term Weight Change after Initiating Second-Generation Antidepressants.
  Arterburn D, Sofer T, Boudreau DM, Bogart A, Westbrook EO, Theis MK, Simon G, Haneuse S. Arterburn D, et al. J Clin Med. 2016 Apr 13;5(4):48. doi: 10.3390/jcm5040048. J Clin Med. 2016. PMID: 27089374 Free PMC article.
• Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
  de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. de Bodinat C, et al. Nat Rev Drug Discov. 2010 Aug;9(8):628-42. doi: 10.1038/nrd3140. Epub 2010 Jun 25. Nat Rev Drug Discov. 2010. PMID: 20577266 Review.
• Associations of self-reported anxiety symptoms with health-related quality of life and health behaviors.
  Strine TW, Chapman DP, Kobau R, Balluz L. Strine TW, et al. Soc Psychiatry Psychiatr Epidemiol. 2005 Jun;40(6):432-8. doi: 10.1007/s00127-005-0914-1. Soc Psychiatry Psychiatr Epidemiol. 2005. PMID: 16003592
• Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
  Barry D, Pietrzak RH, Petry NM. Barry D, et al. Ann Epidemiol. 2008 Jun;18(6):458-66. doi: 10.1016/j.annepidem.2007.12.009. Epub 2008 Mar 10. Ann Epidemiol. 2008. PMID: 18329894 Free PMC article.
• Second-generation antipsychotics and metabolic side-effects: Canadian population-based study.
  Hirsch L, Patten SB, Bresee L, Jette N, Pringsheim T. Hirsch L, et al. BJPsych Open. 2018 Jul;4(4):256-261. doi: 10.1192/bjo.2018.33. BJPsych Open. 2018. PMID: 29998821 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Physicians Postgraduate Press, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information